Healthcare
Starpharma Holdings Limited(SPHRY)
Live Price
Offline$5.00
+8.70% today
1Y Change
+707.02%
Window
Jun 23, 2025 → Jun 15, 2026
- Market Cap
- $300.00M
- Revenue Growth
- -29.4%
- EPS Growth
- -19.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Starpharma Holdings Limited (SPHRY) is a Healthcare stock with a market cap of $300.00M and listed on OTC. The stock last traded around $5.00 and up 707.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -29.4%, EPS growth of -19.5%, a dividend yield of 0.0%. What stands out right now is revenue -29.4%, EPS -19.5%, free cash flow +3.8% with operating margin -100.1% and ROIC -25.2%. Valuation already assumes a fairly strong business story at price/sales 21.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPHRY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-29.4% vs +7.6% peer median
Operating Margin
Below sector median
-100.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -29.4% and EPS is at -19.5%, with operating margin around -100.1%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPHRY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPHRY Max Drawdown
-23.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SPHRY and SPY.
Company Overview
Starpharma Holdings Limited
Other OTC
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
- Leadership
- Cheryl Maley
- IPO Date
- May 4, 2007
- Employees
- 40
- Street Address
- 4-6 Southampton Crescent
- Mailing
- Abbotsford, VIC, 3067
- Region
- Abbotsford, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 8532 2700
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 21.0
- Price/Book
- 13.8
Growth
- Revenue
- -29.4%
- EPS
- -19.5%
- Free Cash Flow
- +3.8%
Profitability
- Gross Margin
- 60.1%
- Operating Margin
- -100.1%
- Net Margin
- -22.7%
- ROE
- -16.0%
- ROIC
- -25.2%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 5.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.